Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM51OQW)

Drug Name
Oxprenolol Drug Info
Synonyms
Coretal; Koretal; Laracor; Osprenololo; Oxprenololum; Tevacor; Trasacor; Trasicor; Osprenololo [DCIT]; Slow Trasicor; Trasicor 80; Captol (TN); Corbeton (TN); Coretal (TN); Dl-Alprenolol; Dl-Oxprenolol; Laracor (TN); Oxprenolol (INN); Oxprenolol (TN); Oxprenolol [INN:BAN]; Oxprenololum [INN-Latin]; Slow-pren; Tevacor (TN);Trasacor (TN); Trasicor (TN); Trasidex (TN); Trasitensin (TN); Slow-Pren (TN); Slow-Trasicor (TN); Coretal (*hydrochloride*); Laracor (*hydrochloride*); Oxprenolol Ba 39089 (*hydrochloride*); Trasacor (*hydrochloride*); Trasicor (*hydrochloride*); Slow-Pren (*hydrochloride*); (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-Oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)-2-propanol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol
Indication
Disease Entry ICD 11 Status REF
Anxiety Approved [1]
Hypertension BA00-BA04 Approved [2]
Long QT syndrome BC65.0 Approved [1]
Malignant essential hypertension BA00 Approved [1]
Therapeutic Class
Antihypertensive Agents
Cross-matching ID
PubChem CID
4631
ChEBI ID
CHEBI:91704
CAS Number
CAS 6452-71-7
TTD Drug ID
DM51OQW
VARIDT Drug ID
DR00697
INTEDE Drug ID
DR1216

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor beta-1 (ADRB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propranolol DM79NTF Angina pectoris BA40 Approved [7]
Epinephrine DM3KJBC Acute asthma CA23 Approved [8]
Norepinephrine DMOUC09 Alopecia ED70 Approved [9]
Atenolol DMNKG1Z Angina pectoris BA40 Approved [3]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [3]
Metoprolol DMOJ0V6 Acute coronary syndrome BA41 Approved [3]
Timolol DM3NXRU High blood pressure BA00 Approved [10]
Isoproterenol DMK7MEY Atrioventricular block Approved [11]
Betaxolol DM6EUL5 Hypertension BA00-BA04 Approved [12]
Sotalol DML60TN Sinus rhythm disorder BC9Y Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [14]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [15]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [16]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [17]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [18]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [19]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [20]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [21]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [22]
Propranolol DM79NTF Angina pectoris BA40 Approved [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Renin (REN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [24]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [25]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [26]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [27]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [28]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [29]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [30]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [31]
Epinephrine DM3KJBC Acute asthma CA23 Approved [32]
Chlorthalidone DM4DMBT Edema MG29 Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Vasopressin-neurophysin 2-copeptin (AVP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [34]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [35]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [36]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [37]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [38]
Luvox DMJKROX Anxiety disorder 6B00-6B0Z Approved [39]
Sodium chloride DMM3950 Skin burns ME65.0 Approved [40]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [35]
Chlorpropamide DMPHZQE Non-insulin dependent diabetes 5A11 Approved [41]
Indomethacin DMSC4A7 Bursitis Approved [42]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Antagonist [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [5]
Vasopressin-neurophysin 2-copeptin (AVP) OTAVZ76K NEU2_HUMAN Gene/Protein Processing [6]

References

1 Oxprenolol FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7255).
3 Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
4 Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
5 Mediation of renin release in essential hypertension by alpha-adrenoreceptors. J Cardiovasc Pharmacol. 1981 Nov-Dec;3(6):1153-61. doi: 10.1097/00005344-198111000-00001.
6 Increased plasma vasopressin and serum uric acid in the low renin type of essential hypertension. Acta Med Scand. 1984;215(2):165-72. doi: 10.1111/j.0954-6820.1984.tb04988.x.
7 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
8 Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
9 Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
10 Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
11 Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
12 beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
13 beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
14 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
15 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
16 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
20 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
21 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
22 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
23 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
24 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
25 Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
26 Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
27 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
28 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
29 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
30 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
31 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
32 Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
33 Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
34 [Increased secretion of vasopressin and edema formation in high dosage methotrexate therapy]. Z Gesamte Inn Med. 1988 Aug 1;43(15):411-4.
35 Blood pressure and vasopressin in progressive autonomic failure. Response to postural stimulation, L-dopa and naloxone. Brain. 1983 Jun;106 (Pt 2):503-11. doi: 10.1093/brain/106.2.503.
36 Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. Biol Psychiatry. 1987 Apr;22(4):453-62. doi: 10.1016/0006-3223(87)90167-3.
37 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
38 Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. Blood Press. 2002;11(6):377-84. doi: 10.1080/080370502321095357.
39 [Three cases of severe hyponatremia under taking selective serotonin reuptake inhibitor (SSRI)]. Nihon Jinzo Gakkai Shi. 2000 Oct;42(8):644-8.
40 Osmoregulation of vasopressin and thirst: comparison of 20% mannitol with 5% saline as osmotic stimulants in healthy man. Clin Endocrinol (Oxf). 1994 Aug;41(2):207-12. doi: 10.1111/j.1365-2265.1994.tb02531.x.
41 Inappropriate secretion of antidiuretic hormone induced by chlorpropamide. Am J Med Sci. 1972 Mar;263(3):137-41. doi: 10.1097/00000441-197203000-00002.
42 Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. Pediatr Nephrol. 2005 Nov;20(11):1552-6. doi: 10.1007/s00467-005-2022-6. Epub 2005 Aug 17.